Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
Executive Summary
FDA notified the company the US review goal date for the psoriasis pill has been extended three months from Nov. 16 to Feb. 16.
You may also be interested in...
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Psoriasis treatment brodalumab is first novel biologic approved since US FDA released its final guidance on nonproprietary naming for new biologics and biosimilars; agency says it didn't want to delay the approval by taking more time to develop a suffix.
Siliq US Approval Expected To Make Little Dent In Valeant Debt Mountain
A Black Box warning on suicidal ideation and behavior, a REM program and a Medication Guide may hold back the sales growth of Valeant’s new psoriasis therapy in the US, Siliq, following its Feb. 15 approval, although the drug has been associated with high levels of total skin clearance, a finding that could differentiate it from competing products.
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.